India’s pharma industry is set to boost its generic power as the patent on a key ingredient of blockbuster weight loss drugs expires today.
More than 40 Indian drugmakers are preparing to launch more than 50 brands that will compete with Ozempic and Vegovy at half the price. The impending supply abundance is expected to democratize access in a notoriously price-sensitive market, while concerns are growing over regulatory oversight and the potential for widespread drug abuse.
The stakes are huge. India, the world’s most populous country, has the second-highest burden of diabetes globally after China – 450 million of us could be obese or overweight by 2050, according to The Lancet. Pharmarack estimates India’s obesity drug market to grow broadly ₹Rs 1,500 crore today ₹8,000 crore by 2030.
Ozempic, Vegovi, Monjaro at half price
India’s generic drugmakers – renowned globally for their ability to produce low-cost drugs on a large scale – are preparing to aggressively corner the market. Analysts estimate that these generic brands will start at deep discounts of at least 50% to 60% compared to branded counterparts like Novo Nordisk’s Vegovy and Ozempic, or Eli Lilly & Co.’s Monzaro.
The monthly cost of the lowest dose of semaglutide – the key active pharmaceutical ingredient (API) whose patent expires today – is expected to be less than ~ ₹Range from Rs 11,000 to ₹from 3,000 ₹5,000 almost instantly. As production increases, prices may eventually come down ₹1,500 more ₹2,500.
This rapid deflation is set to radically expand the consumer base. “Patients in the lower economic strata could be included in branded generics,” Pharmarack commercial vice president Sheetal Sapele told Reuters, though she cautioned that corporate profitability would depend heavily on maintaining pricing discipline amid the glut.
lots of options
Industry giants including Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Lupine Ltd, Mankind Pharma and Alkem Laboratories Ltd are vying for market share.
Instead of engaging in a single price war, some top-tier companies are taking advantage of strategic co-marketing agreements to strengthen distribution. In a major precautionary move earlier this week, Zydus Lifesciences Ltd and Torrent Pharmaceuticals Ltd entered into a licensing agreement to co-market semaglutide injection.
Under the terms of the deal, Zydus Lifesciences will manufacture an innovative formulation – a 15 mg/3 ml pre-filled cartridge to be used with a reusable pen – while Torrent Pharma secures semi-exclusive rights to market the drug under the brand name Symbolic. The upfront licensing fee structure allows Zydus to monetize its manufacturing capacity, while Torrent Pharma leverages its huge domestic field strength in chronic therapies.
While the influx of generic drugs is a boon for affordability, health care analysts are sounding the alarm over the possibility of a regulatory “Wild West.” Semaglutide is still a prescription-only drug, but pharmaceutical enforcement in India has historically been weak.
“With high demand, falling prices and multiple brands, you could see direct pharmacy purchases, distributor-level leakage, or cosmetic or lifestyle use, especially in urban markets,” Salil Kalianpur, an independent pharma analyst, told Reuters.
Kalliyanpur argues that such unstructured access can lead to poor dose titration, unmanaged side effects and, ultimately, regulatory strictures by the state.
survival of the fittest
The immediate consequences of a patent cliff will be chaotic. The market will be filled with “SEMA”-branded derivatives, aggressive marketing campaigns, and overwhelming prescribers with varying device quality.
However, in India’s physician-driven pharmaceutical ecosystem, long-term success will depend on clinical trust rather than just minimum pricing.
Doctors acting as gatekeepers are expected to eventually consolidate their prescriptions around a handful of trusted players who can guarantee supply chain integrity and consistent patient outcomes.
The clock is already ticking for the dozens of companies entering the fray today. “Weak players with poor quality and no discrimination will be out within two to three years,” Kalianpur said.